Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison
Journal of Infection and Public Health2021Vol. 14(8), pp. 985–989
Citations Over TimeTop 10% of 2021 papers
Dujana Mostafa Hamed, Khawla Mohammad Belhoul, Naama Abdelrahman Al Maazmi, Farah Ghayoor, Muneeba Moin, Mahra Al Suwaidi, Meeruna Narainen, Maryam Makki, Mahera Abdulrahman
Abstract
In patients with severe COVID-19 pneumonia on oxygen support, administration of MP daily for 7 days had reduced mortality at 45 days and was associated with significantly lower ICU admission and ventilation rates compared with usual. Adding tocilizumab to MP did not improve any of the studied outcomes significantly.
Related Papers
- → Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence(2021)58 cited
- → COVID‐19: What type of cytokine storm are we dealing with?(2020)21 cited
- → Modulation of Covid‐19 cytokine storm by tocilizumab(2021)15 cited
- → Methylprednisolone continuous infusion versus tocilizumab in treatment of hospitalized COVID‑19 patients: Retrospective data analysis and comparison of effects(2022)4 cited
- → Role of Tocilizumab in the Treatment of COVID-19 Patients with Cytokine Storm: A Case Series(2022)2 cited